González San Segundo, C.López-Campos, FernandoGómez Iturriaga, AlfonsoSantos, M.Ocanto, AbrahamsMontezuma, L.Boladeras-Inglada, A. M.Glaria, M.Duque Santana, VíctorCouñago Lorenzo, FelipeEt. al.2025-12-092025-12-092025González San Segundo, C., López-Campos, F., Gómez Iturriaga, A., Santos, M., Ocanto, A., Montezuma, L., Boladeras-Inglada, A. M., Glaria, L., Guardado, S., Rodríguez, A., Henríquez, I., Olivera, J., Duque-Santana, V., Garre, J., Moreno, S., Valero, J., Conde, A. J., Doval, A., Sancho, G., … Couñago, F. (2025). Duration of androgen deprivation therapy with salvage radiotherapy in patients with prostate cancer and biochemical recurrence after surgery: Initial recruitment data in the phase III URONCOR 06-24 trial. Actas Urológicas Españolas (English Edition), 49(7), 501823. https://doi.org/10.1016/j.acuroe.2025.5018232173-5786https://hdl.handle.net/11268/16587URONCOR 06-24 (NCT05781217) is a prospective, multicenter, randomized, open-label, phase III trial evaluating the impact on distant metastasis-free survival (MFS) of short-term (6 months) versus long-term (24 months) androgen deprivation therapy (ADT) in combination with salvage radiotherapy in high- and intermediate-risk patients after biochemical recurrence (BCR). A total of 534 men will be randomized to receive either 6 or 24 months of ADT. Stratification is based on risk group (intermediate vs high) and nodal status (pN0 vs pNx).engNeoplasias de la próstataEnsayo clínico fase IIIRecuperación mejorada después de la cirugíajournal article10.1016/j.acuroe.2025.501823embargoed accessInvestigación médicaCáncerTratamiento médicoGoal 3: Ensure healthy lives and promote well-being for all at all ages